Cantor Fitzgerald Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Neutral

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by investment analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a report released on Wednesday,Briefing.com Automated Import reports. They presently have a $36.00 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $57.00. Cantor Fitzgerald’s price target suggests a potential downside of 9.43% from the company’s previous close.

Supernus Pharmaceuticals Trading Up 1.6 %

NASDAQ SUPN opened at $39.75 on Wednesday. The firm has a market capitalization of $2.19 billion, a P/E ratio of 37.15 and a beta of 0.90. The business has a fifty day simple moving average of $37.64 and a 200 day simple moving average of $35.28. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28.

Insider Activity at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 9.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Vident Advisory LLC increased its position in shares of Supernus Pharmaceuticals by 2.2% during the 4th quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock valued at $520,000 after purchasing an additional 309 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 352 shares during the last quarter. Summit Investment Advisors Inc. increased its position in shares of Supernus Pharmaceuticals by 7.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock valued at $190,000 after purchasing an additional 369 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Supernus Pharmaceuticals by 6.6% during the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock worth $275,000 after acquiring an additional 473 shares during the period. Finally, Exchange Traded Concepts LLC grew its stake in shares of Supernus Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock worth $800,000 after acquiring an additional 560 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.